^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
trastuzumab biosimilar
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Noritsu Koki
Drug class:
HER2 inhibitor
Related drugs:
over2years
Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer. (PubMed, Appl Biochem Biotechnol)
The patients then received standard NACT therapy: adriamycin and cyclophosphamide and paclitaxel (AC-T) or AC-TH (AC-T+ Trastuzumab) regimen. The ROC curves to discriminate good neoadjuvant chemotherapy efficiency (Miller-Payne 4-5) and poor efficiency (Miller-Payne 1-3) were created, and AUC value was 0.77. Our results suggested that ctDNA mutation of XRCC1 44055726 (TG>-) might be a positive biomarker for NACT therapy in LABC, while mTOR 11249132(G>C) mutation was potentially associated with NACT resistance.
Journal • BRCA Biomarker • Circulating tumor DNA
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • MTHFR (Methylenetetrahydrofolate Reductase) • XPC (XPC Complex Subunit, DNA Damage Recognition And Repair Factor) • XRCC1 (X-Ray Repair Cross Complementing 1)
|
TP53 mutation • PIK3CA mutation • MTOR mutation
|
Herceptin (trastuzumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • trastuzumab biosimilar
Share via
